Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Paediatric Primary Progressive Multiple Sclerosis: fact or fiction?
Multiple Sclerosis
P11 - Poster Session 11 (8:00 AM-9:00 AM)
9-007
To describe six patients presenting prior to the age of 18 years with a progressive disease course, neuroimaging features typical of adult MS, and positive CSF oligoclonal bands (OCB), thereby fulfilling the 2017 McDonald Criteria.
Previous cohort studies on pediatric multiple sclerosis (MS) have reported very low frequencies for a primary progressive MS (PPMS) course ranging from 0 to 7%. 
Patients were identified from the National Hospital for Neurology and Neurosurgery in London (UK) and the UK Childhood Inflammatory Demyelination network. Medical notes were Two retrospectively reviewed.

A total of six patients (5 male, 1 female) with a diagnosis of PPMS with disease onset before the age of 18 years were identified. 

Patients presented at a median age of 15.5 years (range: 11-17 years), with at least one-year history of progressive deterioration of their balance (n=2) or progressive worsening of lower limb function (n=4). Dissemination in space on first MRI was seen in all patients. CSF OCB were detected in 5/5 patients tested. 

At 2-years, all patients developed lower limb spasticity, three patients developed cognitive difficulties, three had visual problems and three had bladder involvement. Median EDSS was 5.5 (range: 4 to 7.5).

Three patients (50%) had relapses during the progressive clinical course, two with new onset visual symptoms and one with worsening leg weakness and urinary symptoms.

All patients showed new lesions on repeat MRI imaging. Contrast enhancement was present in 3/4 (75%) during the disease course. 

Presentation with progressive neurological symptoms and signs in young people should prompt evaluation for genetic causes such as leukodystrophies, hereditary spastic paraparesis and mitochondrial diseases given the rarity of primary progressive course in pediatric MS. In the absence of an alternative diagnosis, with new therapeutic options becoming available for PPMS, this diagnosis should then be considered. 

Authors/Disclosures
Yael Hacohen, MBBS (Great Ormond Street Hospital)
PRESENTER
Dr. Hacohen has nothing to disclose.
Omar Abdel-Mannan, MD (Great Ormond Street Hospital) Dr. Abdel-Mannan has nothing to disclose.
Rosa Cortese (University of Siena) No disclosure on file
No disclosure on file
Cheryl Hemingway Cheryl Hemingway has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Cheryl Hemingway has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Cheryl Hemingway has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
Alan J. Thompson, MD, FRCP, FÂé¶¹´«Ã½Ó³»­ (UCL Institute of Neurology) No disclosure on file
Wallace Brownlee, MD Dr. Brownlee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Brownlee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Brownlee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Brownlee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Brownlee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Brownlee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Brownlee has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Sage.
Olga Ciccarelli, MD, PhD, FRCP (UCL Institute of Neurology) Prof. Ciccarelli has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Prof. Ciccarelli has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NEUROLOGY Journal.